Investigating the role of tumor cell heterogeneity and angiogenesis genes in the prognosis of multiple myeloma

Investigating the role of tumor cell heterogeneity and angiogenesis genes in the prognosis of multiple myeloma

BackgroundMultiple myeloma (MM) is a common hematologic malignancy characterized by high tumor cell heterogeneity, which significantly impacts the clinical prognosis of patients. Angiogenesis and the molecular features of tumor cells play a critical role in tumor progression and drug resistance. Thi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xue Qiao, Zhengrong Song, Li Geng, Lina Xing, Ying Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Immunology
Subjects:	multiple myeloma tumor cell heterogeneity angiogenesis genes prognostic model single -cell analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1610833/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Angiogenesis and multiple myeloma: Exploring prognostic potential of adrenomedullin
by: Angelos Giannakoulas, et al.
Published: (2024-09-01)

Prognostic signature based on mitochondria- and angiogenesis-related genes associated with immune microenvironment of multiple myeloma
by: Dai Zhang, et al.
Published: (2025-12-01)

Construction and validation of a prognostic model of angiogenesis-related genes in multiple myeloma
by: Rui Hu, et al.
Published: (2024-10-01)

Flower-Shaped Plasma Cells in Multiple Myeloma with Morphological Heterogeneity
by: Hiroki Hosoi, et al.
Published: (2024-10-01)

Comprehensive analysis of plasma cell heterogeneity and immune interactions in multiple myeloma
by: Shuang Qu, et al.
Published: (2025-04-01)

CHARACTERISTICS OF BONE MARROW MICROENVIRONMENT IN MULTIPLE MYELOMA BEFORE AND AFTER TREATMENT
by: V. I. Rugal, et al.
Published: (2019-03-01)

Dissecting the endothelial cell landscape in meningioma: single-cell insights into PLVAP+ subpopulations and their role in tumor angiogenesis
by: Liang Zhao, et al.
Published: (2025-05-01)

Single-cell proteomic analysis reveals Multiple Myeloma heterogeneity and the dynamics of the tumor immune microenvironment in precursor and advanced states
by: Mohamed Kamal, et al.
Published: (2025-08-01)

Nestin in multiple myeloma: emerging insights into a potential therapeutic target
by: Yingmiao Wu, et al.
Published: (2025-07-01)

Cytogenetic risk stratification combined with minimal residual disease status influences the therapeutic outcome and prognosis of multiple myelomas
by: Jianping Mao, et al.
Published: (2025-04-01)

Multiple myeloma and cardiovascular risk (a literature review)
by: B. B. Samura, et al.
Published: (2020-11-01)

CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
by: Tong Yu, et al.
Published: (2025-02-01)

Multiple myeloma: A closer look at one of its faces
by: Radu Chiriac, et al.
Published: (2025-02-01)

Leveraging a disulfidptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma
by: Bingxin Zhang, et al.
Published: (2025-04-01)

Integrative analysis of bulk and single-cell gene expression profiles to identify bone marrow mesenchymal cell heterogeneity and prognostic significance in multiple myeloma
by: Fei-Er Ju, et al.
Published: (2025-06-01)

Cardiovascular events after polychemotherapy of multiple myeloma: modern ways to diagnostics
by: B. B. Samura, et al.
Published: (2020-03-01)

Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study
by: Dong Liang, et al.
Published: (2025-12-01)

Clinical Characteristics and Prognostic Value of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Patients in China
by: Geng C, et al.
Published: (2025-05-01)

Targeting BCMA in multiple myeloma: designs, challenges, and future directions
by: Yi Hu, et al.
Published: (2025-02-01)

Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword
by: Sina Kamrani, et al.
Published: (2025-03-01)

Enhancing prognosis in multiple myeloma bone disease: insights from a retrospective analysis of surgical interventions
by: Xiangjun Shi, et al.
Published: (2024-12-01)

Mesenchymal Stem Cells and Reticulated Platelets: New Horizons in Multiple Myeloma
by: Cristian Alejandro Mera Azaín, et al.
Published: (2024-11-01)

Clinical pathway for diagnosis and treatment of new diagnosed multiple myeloma in Guangxi
by: The Control Center of Medical Quality of Guangxi Hematology, et al.
Published: (2025-04-01)

Construction and validation of a prognostic model based on cuproptosis-related genes in patients with multiple myeloma
by: KANG Zhongmin, et al.
Published: (2025-07-01)

T-Cell Engagers In Multiple Myeloma: A Clinical Review
by: Al-Jarrad A, et al.
Published: (2025-03-01)

Prognostic Significance of Neutrophil to Lymphocyte Ratio in Multiple Myeloma Patient
by: Daniela DIACONESCU, et al.
Published: (2025-06-01)

Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
by: Faroogh Marofi, et al.
Published: (2021-03-01)

Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy
by: Goel U, et al.
Published: (2025-02-01)

Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy
by: Ye. I. Darskaya, et al.
Published: (2014-07-01)

MASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma
by: Fan Yang, et al.
Published: (2025-12-01)

Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
by: Asis Shrestha, et al.
Published: (2025-04-01)

Creation of a collection of blood samples of patients with multiple myeloma
by: N. V. Gnennaya, et al.
Published: (2022-01-01)

Research progress of the immunosuppressive tumor microenvironment in multiple myeloma
by: Yue WANG, et al.
Published: (2025-08-01)

Autologous Hematopoietic Cell Transplant as an Effective Treatment Modality for Systemic Sclerosis and Multiple Myeloma
by: Memon H, et al.
Published: (2025-01-01)

Autologous stem cell transplantation in patients older than 65 years with multiple myeloma: a real-world study
by: Cristian Maximiliano Seehaus, et al.
Published: (2024-12-01)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
by: Lina Zhang, et al.
Published: (2021-01-01)

Deciphering the bone marrow microenvironment’s role in multiple myeloma immunotherapy resistance
by: Nicolas Thomas Iannozzi, et al.
Published: (2025-07-01)

Evolving role of high dose stem cell therapy in multiple myeloma
by: Ajay Gupta, et al.
Published: (2011-01-01)

Bioinformatics analysis of intrinsic drivers of immune dysregulation in multiple myeloma to elucidate immune phenotypes and discover prognostic gene signatures
by: Chuan-Feng Fang, et al.
Published: (2025-05-01)

Prognosis of multiple myeloma patients based on histopathological evaluation of bone marrow
by: Niloofar Arefi Sigaroudi, et al.
Published: (2025-06-01)